Navigation Links
Gene-Eden-VIR Has Best Value; polyDNA Compares Treatments for HPV Infection
Date:4/29/2013

Rochester, NY (PRWEB) April 29, 2013

polyDNA recommends Gene-Eden-VIR as the most cost effective means of treating a latent HPV infection. During Money Smart Week (1), polyDNA is doing its part by contrasting the cost of HPV treatments. One of those treatments is Gene-Eden-VIR, a natural remedy against the latent HPV virus.

This week, the media, government agencies, not-for-profits, schools, financial institutions and businesses of all kinds are working together to help customers manage their personal finances better. To help customers who suffer from HPV infections, polyDNA compared the cost of Gardasil, Cervarix and Gene-Eden-VIR. The first two are FDA approved vaccines while the third is a natural, antiviral remedy.

“All my friends have been getting the HPV jab. But, I’ve been waiting it out. I’ve read some stuff online about the studies done on them, Gardasil for sure, only lasts for like…5 years. Then you know, it only protects against 4 strains and I read that there are more than 40 types that can infect the genitals, so for $390, it sounds like Gardasil’s protection is super limited.” -Irene D.

The only FDA drugs approved for HPV prevention are Gardasil and Cervarix. Both are vaccines. Gardasil protects against four HPV strains, and Cervarix protects against two. Neither vaccine is effective if someone is already infected with one of these HPV strains. (2)(3)

According to Cancer.org, the cost of Gardasil is $130 per dose, and it requires at least 3 doses for a person to be considered fully vaccinated. This means that the full cost of vaccination with Gardasil is $390.00. (4)

In 2011 the cost of Cervarix was lowered from $134.95 to $90.00 per dose. (5) However, even at $90.00 per dose, (again at 3 doses for full vaccination) Cervarix comes to a total of $270.00. That’s $120.00 less than Gardasil, but for some customers this cost is still significant.

Gene-Eden-VIR is an ant
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Gene-Eden-VIR is Most Cost Effective; polyDNA Compares Treatments for Herpes Infection
2. GYT and Take Gene-Eden-VIR; polyDNA Recommends an HPV Remedy to Infected Individuals
3. Newly-Published Study Compares SURFAXIN LS™ and CUROSURF® in Well-Established Model of Respiratory Distress Syndrome
4. Study Says Kidney Bean Leaves Work Against Bed Bugs, My Cleaning Products Compares Its With a Non-Pesticide Bed Bug Spray
5. Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response
6. LoneStar Heart Acquires Worldwide Exclusive Rights to New Class of Small Molecules That May Lead to New Treatments for Diabetes
7. Atlanta LASIK Surgeon Dr. Ashraf Releases YouTube Videos Featuring Patient Testimonials and Discussion of Common Eye Treatments
8. Lung Cancer Survivors Share Stories of Value of Early Detection and Hope for More Effective Treatments
9. Only 16% of Donations go to New Cancer Treatments in Some Charities. With cureLauncher, 91% of Contributions Go Directly to New Cures for Cancer.
10. CureLauncher is Described on LIVESTRONG Blog as Modern Platform That Gets People Involved in Advancing New Cancer Treatments
11. Bacterias hidden skill could pave way for stem cell treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 With only 2 weeks left ... on Sartorius Biohit products . The product specials include ... Electronic Pipette Trade-in Program, and free pipette tips. , ... around the world. They are ideal for lab technicians ... ,     Full volume range of 0.1 uL ...
(Date:12/17/2014)... New York, NY (PRWEB) December 16, 2014 ... undergone significant changes since 2013, which is why IBISWorld ... one, this industry continues to benefit from an intensified ... 2014, the proposal for new emission standards for power ... affected industry operators. According to IBISWorld Industry Analyst Sarah ...
(Date:12/17/2014)... Once more, EMAAR has selected BioShaft ... water treatment plant to phase one of BayLaSun, a ... years ago Bioshaft successfully supplied and operated a packaged ... towers with an occupancy of 900 residences. The ... per day and was signed on September 16th, 2014, ...
(Date:12/17/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... the next step in its expanded strategy to rebuild ... the naming of current Chief Operating Officer, Valerie ... current Chairman of the Board and CEO James ... changes are effective January 1, 2015. "Jim ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4
... law firm of Finkelstein,Thompson LLP announces that a class ... Court for the Southern District of New York on,behalf ... GPC Biotech AG,("GPC Biotech" or the "Company") (Nasdaq: ... inclusive (the "Class Period"). Finkelstein Thompson LLP,is investigating similar ...
... BioSciences Inc.,(AMEX: YMI , TSX: YM, AIM: ... differentiated products for patients worldwide,today announced that Oncoscience ... of the humanized EGFR-targeting monoclonal antibody,nimotuzumab, has advised ... commence in Europe. - A ...
... -- Sinovac Biotech Ltd. (Amex:,SVA), a leading ... shareholders today that the Annual General Meeting ... been postponed due the geographical,nature of its ... of,proxy materials. The Company is currently working ...
Cached Biology Technology:Finkelstein Thompson LLP Announces GPC Biotech AG Investigation 2YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 2YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 3YM BIOSCIENCES', EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER 4Sinovac Announces Postponement of Annual General Meeting 2
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/4/2014)... Dec. 3, 2014  Crossmatch™, a leading provider ... its DigitalPersona ® Pro Enterprise software and ... deployed throughout First Bank branch locations in ... Carolina and Virginia. First Bank, a progressive ... Pines, North Carolina , selected the Crossmatch ...
(Date:12/3/2014)... , Dec. 2, 2014 As part ... readers, Inception Technologies is pleased to announce the release ... for customers to collect the workforce data that they ... that have been left by existing readers. Many such ... interface, connectivity and modern technology. Older models force users ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2
... Stanford University research team has been awarded $6.27 million ... to be more energy efficient at home. The funding, ... U.S. Department of Energy,s Advanced Research Projects Agency-Energy (ARPA-E), ... come from Stanford and the California Energy Commission. ...
... skeleton made of segments, the vertebrae. During development of the embryo, ... head-end to the tail-end: the first segments to be added become ... ribs and the last ones the vertebra located in the tail ... it is crucial that, on the one hand, each segment, as ...
... October 27 2009 - The Government of Nepal announced today ... Landscape by 900 sq km, which will increase critical habitat ... at the inaugural session of the Kathmandu Global Tiger Workshop. ... government would establish a National Tiger Conservation Authority as well ...
Cached Biology News:Stanford researchers awarded $6.27 million to study energy efficiency and human behavior 2The skeleton: Size matters 2Nepal expands critical tiger habitat 2
... Reagent A - Fixation medium Reagent B ... intended for fixing cells in suspension with ... with Reagent B. This procedure gives antibodies ... morphological scatter characteristics of the cells intact. ...
... polyclonal to JNK1 (phospho T183 + Y185) ... domain containing phosphorylated T183/Y185. Reactivity / Specificity ... yet tested in other species. Background Information ... the ERK, JNK, and p38 kinases. The members ...
... Dako Target Retrieval Solution, pH 9 (x ... buffer, pH 9, intended for heat-induced target ... is well-suited for use on formalin-fixed, paraffin-embedded ... with 0.01 mol/L citrate buffer, pH 6, ...
... been designed to provide a thin film-like barrier when ... slide. This barrier creates the proper surface tension ... on the slide. PAP Pen contains a special ... It can be removed, if desired, by xylene after ...
Biology Products: